Myriad Genetics (MYGN) enters an agreement with Pharma Mar, a leader in the development of...

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

Myriad Genetics (MYGN) enters an agreement with Pharma Mar, a leader in the development of marine-derived drugs, to conduct testing on patients to be enrolled in a Phase II clinical study of PM1183, a drug which induces double-stranded DNA breaks to cause cell death. Shares +0.4% AH.